Bones; Tendons; Teeth; Cartilage Patents (Class 530/840)
-
Patent number: 9011930Abstract: Nutritional supplements and methods for maintaining and/or improving the condition of bones or cartilage in a mammal, particularly a human. One such supplement comprises demineralized bone matrix (DBM) wherein the DBM comprises a bone growth improving amount of at least one osteoinductive growth factor. A preferred supplement composition further comprises at least one vitamin, such as vitamin E. One method comprises orally administering to the mammal on a periodic basis a supplement comprising DBM. In a preferred method the DBM composition is periodically administered and there is a further periodic administration of a therapeutically effective amount of a calcium-containing composition; the calcium-containing composition is administered temporally spaced apart from said DBM composition for maximum effectiveness.Type: GrantFiled: May 1, 2006Date of Patent: April 21, 2015Assignee: ZyCal Bioceuticals Healthcare Company, Inc.Inventor: James Scaffidi
-
Patent number: 8829166Abstract: A method for purifying bone-derived osteoinductive proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recover process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and approximately 100 kilodaltons. Processes of the present invention may be used to recover osteoinductive proteins from bone demineralization waste streams.Type: GrantFiled: October 20, 2009Date of Patent: September 9, 2014Assignee: Zimmer Orthobiologics, Inc.Inventors: Kevin Thorne, Rama Akella
-
Patent number: 8551170Abstract: Disclosed are methods for producing implantable bone compositions suitable for attaching stem cells thereto, characterized in that bone particles are contacted with an albumin comprising solution. Said bone particles can be mineralized and/or lyophilized bone particles of animal or human origin. Preferably the non-immunogenic albumin comprising solution is lyophilized onto said bone particles. The invention further concerns bone compositions suitable for use in graft implantation obtainable by said methods.Type: GrantFiled: February 26, 2009Date of Patent: October 8, 2013Assignee: Lacerta Technologies, Inc.Inventors: Zsombor Lacza, Miklós Weszl
-
Patent number: 8452483Abstract: A cell-based vehicle driving control system includes a local server for obtaining road environment information on roads within a cell and target vehicle information on a target vehicle within the cell and generating local waypoints based on the road environment information and the target vehicle information; a global server for monitoring the target vehicle information, the road environment information and local server information on the local server received from the local server; and a vehicle control terminal, mounted in the target vehicle, for receiving the local waypoints from the local server and controlling the target vehicle based on the local waypoints. The road environment information is obtained by using at least one sensor installed on the roads.Type: GrantFiled: June 21, 2010Date of Patent: May 28, 2013Assignee: Electronics and Telecommunications Research InstituteInventors: Do Hyun Kim, Sung Won Sohn, Jong-Hyun Park, Byung Tae Jang, Jeong Dan Choi, Kyung Bok Sung, Kyoung Hwan An, Ju Wan Kim, Seong Ik Cho, Jungsook Kim
-
Patent number: 8119167Abstract: Use of a composition comprising cartilage or chondroitin sulphate and absorbable zinc for the preparation of a food supplement or a drug suitable for promoting iron absorption in patients suffering from lack of iron.Type: GrantFiled: February 20, 2008Date of Patent: February 21, 2012Assignee: Medestea Research & Production S.R.L.Inventor: Gianfranco Merizzi
-
Patent number: 7928059Abstract: Disclosed are a method and a corresponding pharmaceutical composition for treating damaged cartilage and subchondral bone. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of cartilage and bone damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).Type: GrantFiled: May 10, 2006Date of Patent: April 19, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Ray Vanderby, Kelley W. Grorud
-
Patent number: 7847072Abstract: A method for purifying bone-derived osteogenic proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recovery process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and approximately 50 kilodaltons. Processes of the present invention may be used to recover osteogenic proteins from bone demineralization waste streams.Type: GrantFiled: June 21, 2007Date of Patent: December 7, 2010Assignee: Zimmer Orthobiologics, Inc.Inventor: Kevin Thorne
-
Patent number: 7758895Abstract: The present invention provides methods for purifying insoluble bone gelatin and uses for insoluble bone gelatin. The process for isolating insoluble bone gelatin from bone tissue includes grinding the bone tissue into bone powder; washing the bone powder with saline; demineralizing the bone tissue; contacting the bone powder with a neutral salt; and contacting the bone powder with a stabilizer. The present invention also discloses an insoluble bone gelatin including about 10 percent growth factor. Insoluble bone gelatin is useful, for example, in preparing impaction bone grafts.Type: GrantFiled: September 4, 2002Date of Patent: July 20, 2010Assignee: Perth Bone and Tissue BankInventors: Ying Fan, Ming Hao Zheng, David Wood
-
Patent number: 7632684Abstract: In an in vitro diagnostic test for osteoarthritis or rheumatoid arthritis, the amount or presence in a sample of anisomerised or optically inverted protein fragment is measured which derives from perlecan, bigylcan, decorin, fibrillin-1 or protocadherin or which is a specific sequence from aggrecan, type II collagen, COMP or CILP.Type: GrantFiled: May 22, 2002Date of Patent: December 15, 2009Assignee: Nordic Bioscience Diagnostics A/SInventors: Stephan Christgau, Dennis B. Henriksen, Paul A. C. Cloos
-
Patent number: 7622562Abstract: A method for purifying bone-derived osteoinductive proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recovery process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and approximately 100 kilodaltons. Processes of the present invention may be used to recover osteoinductive proteins from bone demineralization waste streams.Type: GrantFiled: October 27, 2006Date of Patent: November 24, 2009Assignee: Zimmer Orthobiologics, Inc.Inventors: Kevin Thorne, Rama Akella
-
Patent number: 7556800Abstract: The current invention involves a universal fishing bait fundamentally comprised of a cord body of filaments or strips of fibrous collagen made up into any shape or design capable of attracting fish, that is 100% biodegradable and that furthermore has a good capacity to diffuse and liberate attractant substances. The bait invented presents excellent mechanical properties in terms of resistance to breakage and resistance to tearing, is easily manipulated, transported and stored. Similarly, the invention provides for the use of fibrous collagen in the preparation of said universal fishing bait.Type: GrantFiled: July 9, 2004Date of Patent: July 7, 2009Assignee: Viscofan, S.AInventors: Vicente Etayo Garralda, Ion Inaki Garcia Martinez
-
Patent number: 7534422Abstract: The current invention involves a universal fishing bait fundamentally comprised of a matrix of fibrous collagen made up into any shape or design capable of attracting fish, that is 100% biodegradable and innocuous, that has physico-chemical properties that confer it with the capacity to accommodate liberate and diffuse attractant substances, and whose physico-mechanical properties confer it a soft and flexible texture, as well as making it resistant to breakage. Likewise, the invention outlines a procedure to prepare such a bait, and a precursor paste employed in the preparation, as well as the use of fibrous collagen in the preparation of said universal fishing bait.Type: GrantFiled: July 9, 2004Date of Patent: May 19, 2009Assignee: Viscofan, S.A.Inventors: Vicente Etayo Garralda, Ion Inaki Garcia Martinez
-
Patent number: 7410770Abstract: A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG, located in the helical region of collagen type II.Type: GrantFiled: March 12, 2003Date of Patent: August 12, 2008Assignee: Universite De LiegeInventors: Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
-
Patent number: 7393649Abstract: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.Type: GrantFiled: March 12, 2003Date of Patent: July 1, 2008Assignee: Universite de LiegeInventors: Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
-
Patent number: 7354723Abstract: Disclosed are compositions and methods for performing an immuno-assay that includes measuring the amount of an isomerised or optically inverted non-collagen protein derived from cartilage.Type: GrantFiled: May 23, 2002Date of Patent: April 8, 2008Assignee: Nordic Bioscience Dagnostics A/SInventors: Stephan Christgau, Dennis B. Henriksen, Paul A. C. Cloos
-
Patent number: 7258999Abstract: This invention relates to a novel PTH gene. The invention further relates to methods of screening, diagnosis and development of therapies for bone related disorders.Type: GrantFiled: November 10, 2003Date of Patent: August 21, 2007Assignee: WyethInventors: John Allen Robinson, Vedrana Stojanovic-Susulic, Philip Babij, Richard John Murrills
-
Patent number: 7241874Abstract: A method for purifying bone-derived osteogenic proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recovery process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and approximately 50 kilodaltons. Processes of the present invention may be used to recover osteogenic proteins from bone demineralization waste streams.Type: GrantFiled: June 25, 2003Date of Patent: July 10, 2007Assignee: Zimmer Ortho Biologics, Inc.Inventor: Kevin Thorne
-
Patent number: 7208469Abstract: We claim a method of treating a patient to stimulate chondrocyte proliferation comprising administering to said patient an adrenomedullin analog that is adrenomedullin-(27–52) wherein said patient is suffering from cartilage disorders, and a method of stimulating chondrocyte proliferation comprising administering to chondrocyte cells adrenomedullin-(27–52).Type: GrantFiled: March 21, 2005Date of Patent: April 24, 2007Assignee: Auckland UniServices LimitedInventors: Ian Reginald Reid, Jillian Cornish
-
Patent number: 7186811Abstract: The present invention is related to an osteogenic device and its preparation. Said device comprises a bone morphogenetic protein (BMP), preferably a modified BMP complex obtainable by a modification of the conventional guanidum hydrochloride extraction method and collagens, preferably collagen I or collagen IV, impregnated in and/or adsorbed on a bioceramic carrier, preferably a shapable body (block) originating from a coral skeleton. The method of isolating said modified BMP complex which lacks an immunogenic component and consists essentially of a 100–700 kD and a 15–25 kD protein with osteoinductive properties and preferably of the 15–25 kD protein which has improved storage properties as well as its use in the osteogenic device with improved osteoinductive properties is also disclosed.Type: GrantFiled: January 20, 2004Date of Patent: March 6, 2007Assignee: Bioactive Bone Substitutes Oy, ABInventors: Sam T. Lindholm, Aulis Marttinen
-
Patent number: 7081240Abstract: A protein mixture that is useful in the treatment of wounds, where the mixture is isolated from bone or is produced from recombinant proteins and may include two or more of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, TGF-?1, TGF-?2, TGF-?3, and FGF-1.Type: GrantFiled: June 28, 2000Date of Patent: July 25, 2006Assignee: Zimmer OrthoBioLogics, Inc.Inventors: Rama Akella, John P. Ranieri
-
Patent number: 6841644Abstract: Disclosed are modified naturally occurring biocompatible biopolymers of plant and animal origin made by subjecting same to ionizing radiation in the presence of a mediating gas, typically acetylene to enable one to selectively enhance and modify one or more of the physiochemical properties of the starting materials which have a wide range of uses in medicine, food technology and other industrial applications. Notwithstanding the modifications, the biocompatibility of the biopolymer remains unchanged and no new or additional functional groups are introduced into the starting biopolymer.Type: GrantFiled: March 28, 2003Date of Patent: January 11, 2005Assignee: Phillips Hydrocolloids Research LimitedInventors: Glyn Owen Phillips, Tjaart Andries Du Plessis, Saphwan Al-Assaf, Peter Anthony Williams
-
Patent number: 6746865Abstract: Nucleic acid sequences encoding for endostatin protein. Ribonucleic and deoxyribonucleic acid sequences that encode for endostatin protein are useful for gene therapy or recombinant expression for the treatment of angiogenesis-related diseases, specifically angiogenesis-dependent cancer.Type: GrantFiled: October 16, 1998Date of Patent: June 8, 2004Assignee: The Children's Medical Center CorporationInventors: Michael S. O′Reilly, M. Judah Folkman
-
Patent number: 6645485Abstract: A process for treating inflammation in a joint whether heat, redness, pain, swelling and/or stiffness, and for increasing motion and increasing joint space and correcting malalignment, comprising the steps of dissolving a quantity of growth hormone (somatotropin), preferably in purified form, in a buffer solution, and injecting one time or multiple repeat times, a single dosage of the mixture of purified growth hormone and buffer solution into the joint of a body so as to initiate the treatment process.Type: GrantFiled: February 2, 2001Date of Patent: November 11, 2003Inventor: Allan R. Dunn
-
Patent number: 6589590Abstract: A method of making artificial bone comprises providing a membrane of collagen with solutions of calcium ions and of phosphate ions on opposite sides of the membrane. The calcium ions and phosphate ions diffuse through the membrane and precipitate as a hydroxyapatite material. Control of ionic concentrations ensures that precipitation takes place within the fibrils of the membrane. The result is an artificial bone material comprising a matrix of collagen and a hydroxyapatite material deposited within the matrix.Type: GrantFiled: February 27, 2002Date of Patent: July 8, 2003Assignee: Isis Innovation LimitedInventors: Jan Tadeusz Czernuszka, Alison Christina Lawson, Alasdair Hamish Robert Wallace Simpson
-
Publication number: 20030109686Abstract: The present invention is based on the discovery that a true tissue morphogen such as OP-1 provided systemically, alone in its mature dimeric form, or as part of a soluble complex, can induce new replacement tissue regeneration at a localized, permissive defect site distal to the site of administration. Specifically, systemically administered protein is sufficient to induce formation of new functional replacement tissue, sufficient to repair a local defect in a tissue, including skeletal or orthopedic tissues, liver, pancreas, lung, cardiac, renal, uterine, intestinal, gastrointestinal _____ tissue. (As used herein, “orthopedic” or “skeletal” or “joint” or “chondrogenic” tissue is understood to encompass the skeletal and skeletal joint tissues: bone, cartilage, tendon, ligament, and synovial membrane tissues.Type: ApplicationFiled: March 8, 2000Publication date: June 12, 2003Inventors: KUBER T. SAMPATH, CHARLES M. COHEN
-
Publication number: 20030069401Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: ApplicationFiled: October 24, 1997Publication date: April 10, 2003Inventors: HERMANN OPPERMANN, ENGIN OZKAYNAK, THANGAVEL KUBERASAMPATH, DAVID C. RUEGER, ROY H. L. PANG
-
Publication number: 20030026786Abstract: Disclosed are a composition of chemically defined components having elevated levels of simple sugars which support the enhanced in vitro chondrogenesis of mesenchymal progenitor cells, a method for in vitro chondrogenic induction of such progenitor cells and a method of forming human chondrocytes in vitro from such progenitor cells.Type: ApplicationFiled: June 4, 1999Publication date: February 6, 2003Inventors: MARK F. PITTENGER, ALASTAIR M. MACKAY, J. MARY MURPHY, FRANCIS P. BARRY
-
Patent number: 6511958Abstract: Disclosed is a cartilage repair product that induces both cell ingrowth into a bioresorbable material and cell differentiation into cartilage tissue. Such a product is useful for regenerating and/or repairing both vascular and avascular cartilage lesions, particularly articular cartilage lesions, and even more particularly mensical tissue lesions, including tears as well as segmental defects. Also disclosed is a method of regenerating and repairing cartilage lesions using such a product.Type: GrantFiled: February 16, 2000Date of Patent: January 28, 2003Assignee: Sulzer Biologics, Inc.Inventors: Brent Atkinson, James J. Benedict
-
Patent number: 6461630Abstract: Disclosed are terminally sterilized osteogenic devices for implantation into a mammal. The devices contain a combination of a biologically active osteogenic protein and an insoluble carrier which after being combined are sterilized by exposure to ionizing radiation, for example, by exposure to gamma rays or an electron beam. The terminally sterilized devices of the invention are characterized in that they induce bone formation following implantation into a mammal. Also disclosed is a method for inducing bone formation in a mammal by implanting a terminally sterilized device of the invention into a preselected locus in a mammal. Also disclosed is a method for preparing the terminally sterilized device of the invention.Type: GrantFiled: November 30, 1999Date of Patent: October 8, 2002Assignee: Stryker CorporationInventors: Marjorie M. Tucker, David C. Rueger, Kuber T. Sampath
-
Publication number: 20020143159Abstract: Purified BMP-17 and BMP-18 proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-17 and BMP-18 proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage, other connective tissue defects and disorders, including tendon, ligament and meniscus, in wound healing and related tissue repair, as well as for treatment of disorders and defects to tissues which include epidermis, nerve, muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver, lung, epithelium, brain, spleen, cardiac, pancreas and kidney tissue. The proteins may also be useful for the induction of growth and/or differentiation of undifferentiated embryonic and stem cells.Type: ApplicationFiled: November 12, 1999Publication date: October 3, 2002Inventors: ANTHONY J. CELESTE, BETH L. MURRAY
-
Patent number: 6368787Abstract: The present invention relates generally to methods and compositions for identifying morphogenic protein analogs. In one embodiment, this invention relates to an osteogenic protein reponsive transcription inhibitory element. This invention also relates to the identified morphogenic protein analogs which can mimic the biological effects of morphogenic proteins, particularly those relating to the BMP family such as osteogenic protein (OP-1), on the regulation of gene expression and tissue inductive capabilities.Type: GrantFiled: December 16, 1999Date of Patent: April 9, 2002Assignee: Stryker CorporationInventors: Lee-Chuan C. Yeh, John C. Lee
-
Patent number: 6287816Abstract: Purified bone morphogenetic protein-9 (BMP-9) proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.Type: GrantFiled: June 6, 1994Date of Patent: September 11, 2001Assignee: Genetics Institute, Inc.Inventors: Vicki A. Rosen, John M. Wozney, Anthony J. Celeste, R. Scott Thies, Jeffrey R. Song
-
Publication number: 20010016646Abstract: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans.Type: ApplicationFiled: March 20, 1998Publication date: August 23, 2001Inventors: DAVID C. RUEGER, MARJORIE A. TUCKER, AN-CHENG CHANG
-
Publication number: 20010014662Abstract: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans.Type: ApplicationFiled: March 20, 1997Publication date: August 16, 2001Inventors: DAVID C RUEGER, MARJORIE A TUCKER
-
Publication number: 20010011127Abstract: The present application relates to a compositions comprising a compound which modulates the activity of T1-M protein, the use of compounds which modulate the activity of T1-M protein, and an in vitro method for influencing the proliferation and/or differentiation potential of bone cells.Type: ApplicationFiled: March 20, 1998Publication date: August 2, 2001Inventors: ANNE KATRIN WERENSKIOLD, JORG SCHMIDT
-
Patent number: 6261586Abstract: A bone graft substitute including a composition of natural selectively deactivated bone material which has been processed to remove associated non-collagenous bone proteins, said bone material containing native collagen materials and naturally associated bone minerals and substantially free from native non-collagenous protein, and a therapeutically effective amount to stimulate bone growth of a bone growth factor in a pharmaceutically acceptable carrier in synergistic combination with said bone material. Spacers composed of the bone graft substitute composition methods for using the spacers are also provided.Type: GrantFiled: August 31, 1999Date of Patent: July 17, 2001Assignee: SDGI Holdings, Inc.Inventor: William F. McKay
-
Patent number: 6180605Abstract: The present invention provides improved osteogenic compositions having enhanced by the sorption of growth factors, of nutrient factors, or drugs onto or into the compositions. Compositions may consist of collagen and demineralized bone materials onto and into which growth factors, antimicrobial agent,s nutrient factors, or other soluble factors may be sorbed to enhance the osteogenic factor. These materials can be used in a wide range of clinical procedures to replace and restore osseous or periodontal defects.Type: GrantFiled: January 5, 1998Date of Patent: January 30, 2001Assignee: GenSci OrthoBiologics, Inc.Inventors: Charles C. Chen, Steven R. Jeffries
-
Patent number: 6180606Abstract: Osteogenic compositions, and methods for preparing same, which compositions comprise a porous or semi-porous matrix, an osteogenic factor and an agent such as growth factors, nutrient factors, drugs, calcium-containing compounds, blood products, large molecular weight proteins, or combinations thereof. These materials can be used in a wide range of clinical procedures to replace and restore osseous or periodontal defects.Type: GrantFiled: January 13, 1998Date of Patent: January 30, 2001Assignee: GenSci Orthobiologics, Inc.Inventors: Charles C. Chen, Steven R. Jefferies
-
Patent number: 6117979Abstract: Bioprosthetic devices made of collagen-based material having collagen amine groups and collagen carboxyl groups are provided as well as methods for their formation. The methods comprise combining an epoxy functionalized crosslinking agent with the collagen-based material in an aqueous medium at an acidic pH to react a portion of the collagen carboxyl groups with the epoxy functionalized crosslinking agent to form crosslinked collagen-based material comprising residual collagen carboxyl groups.Type: GrantFiled: August 18, 1997Date of Patent: September 12, 2000Assignee: Medtronic, Inc.Inventors: Marc Hendriks, Michel Verhoeven, Patrick Cahalan, Raymond Zeeman, Piet Dijkstra, Jan Feijen
-
Patent number: 6034061Abstract: Purified Bone Morphogenetic Protein (BMP)-9 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair, and in hepatic growth and function.Type: GrantFiled: December 4, 1996Date of Patent: March 7, 2000Assignee: Genetics Institute, Inc.Inventors: Vicki A. Rosen, John M. Wozney, Anthony J. Celeste, Scott R. Thies, Jeffrey R. Song
-
Patent number: 5972368Abstract: A bone graft substitute including a composition of natural selectively deactivated bone material which has been processed to remove associated non-collagenous bone proteins, said bone material containing native collagen materials and naturally associated bone minerals and substantially free from native non-collagenous protein, and a therapeutically effective amount to stimulate bone growth of a bone growth factor in a pharmaceutically acceptable carrier in synergistic combination with said bone material. Spacers composed of the bone graft substitute composition methods for using the spacers are also provided.Type: GrantFiled: June 11, 1997Date of Patent: October 26, 1999Assignee: SDGI Holdings, Inc.Inventor: William F. McKay
-
Patent number: 5948766Abstract: Tasteless, hydrolyzed collagen from gelatin, gelatin or animal collagenic connective tissue having an average molecular weight of from 1 to 40 kD for the preparation of agents for the treatment of osteoporosis. It may be combined with conventional agents for combatting osteoporosis, such as calcitonin, calcium salts, and/or progesterone.Type: GrantFiled: April 25, 1997Date of Patent: September 7, 1999Assignee: DGF Stoess AGInventors: Adam Milan, Bernd Eggersgluss, Klaus Braumer, Reinhard Schrieber
-
Patent number: 5936035Abstract: Collagen-based compositions useful in the attachment of tissues, or the attachment of tissues to synthetic implant materials, are disclosed. The compositions comprise collagen crosslinked using a multifunctionally activated synthetic hydrophilic polymer. A particularly preferred composition comprises fibrillar collagen, a fiber disassembly agent, and a multifunctionally activated synthetic hydrophilic polymer. Methods are disclosed for using the compositions to effect the attachment of a native tissue to the surface of another native tissue, a non-native tissue, or a synthetic implant. Also disclosed are methods of using the compositions to prevent the formation of surgical adhesions.Type: GrantFiled: December 18, 1995Date of Patent: August 10, 1999Assignee: Cohesion Technologies, Inc.Inventors: Woonza M. Rhee, Prema R. Rao, George H. Chu, Frank A. DeLustro, Carol F. H. Harner, Naomi Sakai, Jacqueline A. Schroeder
-
Patent number: 5849880Abstract: Purified bone morphogenetic protein (BMP)-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.Type: GrantFiled: June 6, 1995Date of Patent: December 15, 1998Assignee: Genetics Institute, Inc.Inventors: John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen, Anthony J. Celeste
-
Patent number: 5741895Abstract: Disclosed herein is a novel proteinaceous cell density signal molecule (CDS) between 25 and 35 kD, which is secreted by fibroblastic primary avian tendon cells in culture, and causes the cells to self-regulate their proliferation and the expression of differentiated function. It effects an increase of procollagen production in avian tendon cell cultures of ten fold while proliferation rates are decreased. CDS, and the antibodies which recognize them, are important for the development of diagnostics and treatments for injuries and diseases involving connective tissues, particularly tendon. Also disclosed are methods of production and use.Type: GrantFiled: May 19, 1995Date of Patent: April 21, 1998Assignee: The Regents of the University of CaliforniaInventor: Richard I. Schwarz
-
Patent number: 5714589Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: May 23, 1995Date of Patent: February 3, 1998Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 5707962Abstract: The present invention provides improved osteogenic compositions having enhanced by the sorption of growth factors, of nutrient factors, or drugs onto or into the compositions. Compositions may consist of collagen and demineralized bone materials onto and into which growth factors, antimicrobial agent, a nutrient factors, or other soluble factors may be sorbed to enhance the osteogenic factor. These materials can be used in a wide range of clinical procedures to replace and restore osseous or periodontal defects.Type: GrantFiled: September 28, 1994Date of Patent: January 13, 1998Assignee: GenSci Regeneration Sciences Inc.Inventors: Charles C. Chen, Steven R. Jefferies
-
Patent number: 5693615Abstract: A method for generating new bone growth in a mammal comprising administrating to the mammal a safe and effective amount of a Vitamin D compound in combination with a safe and effective amount of osteoinductive extract or at least one BMP.Type: GrantFiled: January 23, 1995Date of Patent: December 2, 1997Assignee: The Procter & Gamble CompanyInventor: Roger Lee Stone
-
Patent number: 5656598Abstract: The present invention provides therapeutic compositions for the prevention and treatment of pathological conditions involving bone and dental tissue. The present invention also provides a method to promote bone repair and/or growth for the treatment of pathological conditions involving bone tissue, for example, osteoporosis, Paget's disease, osteopetrosis, and periodontal disease and fracture repair, and healing of bone defects by administering FGF-1 to an animal or human in need of such treatment.Type: GrantFiled: May 31, 1995Date of Patent: August 12, 1997Assignees: Rhone-Poulenc Rorer Pharmaceuticals Inc., Osteosa Inc.Inventors: Colin R. Dunstan, Elzbieta Izbicka, Gregory R. Mundy, Wilson Burgess, Michael C. Jaye
-
Patent number: 5637466Abstract: A method of detecting bone acidic glycoprotein-75 (BAG-75) antigen includes the steps incubating a serum or synovial fluid sample with anti-BAG antibody, reacting the incubated sample with a signal generating antibody to the anti-BAG-75 antibody, and detecting the signal as an indication of BAG-75 antigen in the serum. Antibodies for use in the test for detecting BAG-75 antigen in serum and synovial fluid samples includes BAG-75 #3-13 peptide anti-serum, anti-BAG-75 protein anti-serum, and monoclonal antibodies against the BAG-75 protein, the antibodies recognizing the 75,000 molecular weight BAG-75 precursor protein and the 50,000 molecular weight BAG-75 fragment in serum and synovial fluid. Molecular weight assignments are based upon electrophoretic mobilities under denaturing conditions.Type: GrantFiled: September 3, 1993Date of Patent: June 10, 1997Assignee: Curators of the University of MissouriInventor: Jeffrey P. Gorski